This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Briasoulis, E. Articles by Pavlidis, N. Search for Related Content PubMed PubMed Citation Articles by Briasoulis, E. Articles by Pavlidis, N.

Cancer of Unknown Primary Origin

Department of Medicine/Oncology Unit, Ioannina University Hospital, Ioannina, Greece

Correspondence: Evangelos Briasoulis, M.D., Department of Medical Oncology, School of Medicine, University of Ioannina, Ioannina 45110, Greece. Telephone: +30-651-99394; Fax: +30-651-46618; e-mail: ebriasou{at}cc.uoi.gr

About 3% of all cancer patients suffer from cancer of unknown primary origin. These patients present with metastatic disease for which a primary site cannot be detected at the time of diagnosis. Sophisticated diagnostic techniques and operational procedures have failed to improve the diagnostic efficacy in this group of patients. Consequently, a limited diagnostic procedure with basic laboratory tests and imaging studies is sufficient for the diagnosis of this syndrome. The use of immunohistochemistry, as well as serum tumor markers of high specificity that may help to identify other tumors, is highly suggested. Although the prognosis for the majority of these patients still remains poor, several subsets of favorable outcome to treatment have been recognized. Nevertheless, promising in vitro data and new drugs on trials, paralleled with a better knowledge of the underlying pathogenetic molecular mechanisms, offer a more optimistic look to the future therapeutic management of these patients.

Key Words. Unknown primary • Unknown origin • Occult cancer • Carcinoma • Metastasis • Incidence • Diagnosis • Treatment

This article has been cited by other articles:

				M. Kodaira, S. Takahashi, S. Yamada, K. Ueda, Y. Mishima, K. Takeuchi, N. Yamamoto, Y. Ishikawa, M. Yokoyama, T. Saotome, et al. Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy Ann. Onc., December 17, 2009; (2009) mdp583v1. [Abstract] [Full Text] [PDF]

				H. Cheng, P. Liu, Z. C. Wang, L. Zou, S. Santiago, V. Garbitt, O. V. Gjoerup, J. D. Iglehart, A. Miron, A. L. Richardson, et al. SIK1 Couples LKB1 to p53-Dependent Anoikis and Suppresses Metastasis Sci. Signal., July 21, 2009; 2(80): ra35 - ra35. [Abstract] [Full Text] [PDF]

				R. W. Tothill, A. Kowalczyk, D. Rischin, A. Bousioutas, I. Haviv, R. K. van Laar, P. M. Waring, J. Zalcberg, R. Ward, A. V. Biankin, et al. An Expression-Based Site of Origin Diagnostic Method Designed for Clinical Application to Cancer of Unknown Origin Cancer Res., May 15, 2005; 65(10): 4031 - 4040. [Abstract] [Full Text] [PDF]

				E. Briasoulis, H. Kalofonos, D. Bafaloukos, E. Samantas, G. Fountzilas, N. Xiros, D. Skarlos, C. Christodoulou, P. Kosmidis, and N. Pavlidis Carboplatin Plus Paclitaxel in Unknown Primary Carcinoma: A Phase II Hellenic Cooperative Oncology Group Study J. Clin. Oncol., September 17, 2000; 18(17): 3101 - 3107. [Abstract] [Full Text] [PDF]